The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

The partnership between the US military and the body and the non-profit will examine three drugs as potential therapies ...

Early detection and public health interventions are critical in improving sepsis survival rates and limiting its long-term ...

MSD has commenced the Phase III trial to assess zilovertamab vedotin combined with R-CHP to treat individuals with previously ...